

Special Issue

Non-Small Cell Lung Cancer Therapies

Message from the Guest Editor

The field of non-small cell lung cancer (NSCLC) has made significant advances over the last decade. This ranges from staging classification, pathological classification, early lung screening, cytotoxic chemotherapy and new targeted treatments that have transformed lung cancer treatment for metastatic disease with molecular biomarkers. We are now entering into the new exciting era of an immunotherapy approach using drugs that can prevent NSCLC cells from evading the immune system. The purpose of this special issue is to summarize and update fellow researchers as to the remarkable progress we have made for NSCLC therapies in the last several years. Both review papers and research papers are welcome.

Guest Editor

Prof. Dr. Siow Ming Lee

Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK

Deadline for manuscript submissions

closed (28 February 2015)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/3804

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)